- Home
- ACAD
as 04-18-2025 1:30pm EST
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
| Founded: | 1993 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 2.8B | IPO Year: | 2004 |
| Target Price: | $23.93 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.40 - $20.68 | Next Earning Date: | 05-07-2025 |
| Revenue: | $957,797,000 | Revenue Growth: | 31.85% |
| Revenue Growth (this year): | 13.07% | Revenue Growth (next year): | 9.88% |
Stock Insider Trading Activity of ACADIA Pharmaceuticals Inc. (ACAD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kihara James | ACAD | PRINCIPAL ACCOUNTING OFFICER | Apr 5 '25 | Sell | $14.82 | 1,028 | $15,234.96 | 22,257 | |
| Kihara James | ACAD | PRINCIPAL ACCOUNTING OFFICER | Mar 24 '25 | Sell | $17.05 | 1,095 | $18,669.75 | 22,257 | |
| Schneyer Mark C. | ACAD | EVP, CHIEF FINANCIAL OFFICER | Mar 24 '25 | Sell | $17.05 | 3,171 | $54,065.55 | 56,889 | |
| GAROFALO ELIZABETH A. | ACAD | Director | Mar 5 '25 | Sell | $18.23 | 4,919 | $89,673.37 | 17,595 | |
| Kihara James | ACAD | PRINCIPAL ACCOUNTING OFFICER | Feb 23 '25 | Sell | $19.96 | 475 | $9,481.00 | 22,257 | |
| Schneyer Mark C. | ACAD | EVP, CHIEF FINANCIAL OFFICER | Feb 23 '25 | Sell | $19.96 | 773 | $15,429.08 | 56,889 |
Latest ACADIA Pharmaceuticals Inc. News
ACAD Breaking Stock News: Dive into ACAD Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
BofA Adjusts Price Target on ACADIA Pharmaceuticals to $18 From $19, Keeps Neutral Rating
Argus Research
4 days ago
ACAD: Raising target price to $16.00
Simply Wall St.
6 days ago
Declining Stock and Solid Fundamentals: Is The Market Wrong About ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)?
Business Wire
8 days ago
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Argus Research
11 days ago
ACAD: Lowering target price to $15.00
Argus Research
18 days ago
ACAD: Lowering target price to $17.00
Argus Research
25 days ago
ACAD: What does Argus have to say about ACAD?
Insider Monkey
25 days ago
Is ACADIA Pharmaceuticals Inc. (ACAD) a Promising Biotech Stock According to Wall Street Analysts
Compare ACAD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACAD ACADIA Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.